Innovating Works

INSTITUTE OF ONCOLOGY AND RADIOLOGY OF S...

Desconocido
EXPAND-EV: EXPANDing the value of Extracellular Vesicles as carriers of biomarker and therapy in precision heal... Extracellular vesicles (EVs) have been identified as important signaling mediators in a myriad of physiological and pathological processes....
2024-08-19 - 2028-12-31 | Financiado
RadExIORSBoost: Twinning to skyrocket scientific excellence towards individual radiosensitivity prediction by raisin... INSTITUT ZA ONKOLOGIJU I RADIOLOGIJU SRBIJE tramitó un HORIZON EUROPE: HORIZON-WIDERA-2023-ACCESS-02 Prostate cancer patients receiving radiotherapy (RT) may develop radiation-induced side effects, which significantly impact quality of life....
2024-05-22 - 2027-09-30 | Financiado
STEPUPIORS: TWINNING FOR A EUROPEAN CONSORTIUM OF RECTAL CANCER RESEARCH INSTITUTIONS THROUGH STEPPING UP SCIENT... INSTITUT ZA ONKOLOGIJU I RADIOLOGIJU SRBIJE tramitó un HORIZON EUROPE: HORIZON-WIDERA-2021-ACCESS-03 "Neoadjuvant chemoradiotherapy (CRT) is the gold standard in locally advanced rectal cancer (LARC), but the response is not uniform among pa...
2022-10-01 - 2025-09-30 | Financiado
STEPUPIORS: TWINNING FOR A EUROPEAN CONSORTIUM OF RECTAL CANCER RESEARCH INSTITUTIONS THROUGH STEPPING UP SCIENT... INSTITUT ZA ONKOLOGIJU I RADIOLOGIJU SRBIJE tramitó un HORIZON EUROPE: HORIZON-WIDERA-2021-ACCESS-03 "Neoadjuvant chemoradiotherapy (CRT) is the gold standard in locally advanced rectal cancer (LARC), but the response is not uniform among pa...
2022-07-14 - 2025-09-30 | Financiado
REPANCAN: Drug repurposing in pancreatic ductal adenocarcinoma INSTITUT ZA ONKOLOGIJU I RADIOLOGIJU SRBIJE tramitó un H2020: H2020-MSCA-IF-2019 The main objective of the REPANCAN is to integrate Jelena Grahovac, PhD at the Institute for Oncology and Radiology of Serbia, as a leader o...
2020-03-24 - 2022-06-30 | Financiado
LungCARD: Blood test for clinical therapy guidance of non small cell lung cancer patients INSTITUT ZA ONKOLOGIJU I RADIOLOGIJU SRBIJE participó en un H2020: H2020-MSCA-RISE-2016 Lung cancer is the most common cancer worldwide. NSCLC alone make up about 75% of all lung cancers and most hospitals currently test all NSC...
2016-12-02 - 2022-10-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.